London
· Delayed Price · Currency is GBP · Price in USD Aclaris Therapeutics Statistics
Total Valuation
LON:0H8T has a market cap or net worth of GBP 96.69 million. The enterprise value is -54.87 million.
| Market Cap | 96.69M |
| Enterprise Value | -54.87M |
Important Dates
The next estimated earnings date is Thursday, May 8, 2025.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +10.73% |
| Shares Change (QoQ) | +33.52% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 66.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.47 |
| PB Ratio | 0.78 |
| P/TBV Ratio | 0.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.52 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 3.40 |
Financial Position
The company has a current ratio of 3.99, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.99 |
| Quick Ratio | 3.88 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.13 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -84.46% and return on invested capital (ROIC) is -20.59%.
| Return on Equity (ROE) | -84.46% |
| Return on Assets (ROA) | -15.72% |
| Return on Invested Capital (ROIC) | -20.59% |
| Return on Capital Employed (ROCE) | -27.83% |
| Revenue Per Employee | 237,349 |
| Profits Per Employee | -1.67M |
| Employee Count | 64 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.10% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -8.10% |
| 50-Day Moving Average | 1.76 |
| 200-Day Moving Average | 1.90 |
| Relative Strength Index (RSI) | 32.09 |
| Average Volume (20 Days) | 1,562 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.92 |
Income Statement
In the last 12 months, LON:0H8T had revenue of GBP 14.95 million and -105.49 million in losses. Loss per share was -1.37.
| Revenue | 14.95M |
| Gross Profit | -24.22M |
| Operating Income | -41.96M |
| Pretax Income | -105.49M |
| Net Income | -105.49M |
| EBITDA | -41.71M |
| EBIT | -41.96M |
| Loss Per Share | -1.37 |
Balance Sheet
The company has 90.74 million in cash and 2.08 million in debt, giving a net cash position of 160.79 million.
| Cash & Cash Equivalents | 90.74M |
| Total Debt | 2.08M |
| Net Cash | 160.79M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 124.25M |
| Book Value Per Share | 1.15 |
| Working Capital | 75.37M |
Cash Flow
In the last 12 months, operating cash flow was -16.04 million and capital expenditures -96,651, giving a free cash flow of -16.13 million.
| Operating Cash Flow | -16.04M |
| Capital Expenditures | -96,651 |
| Free Cash Flow | -16.13M |
| FCF Per Share | n/a |
Margins
| Gross Margin | -161.99% |
| Operating Margin | -280.59% |
| Pretax Margin | -705.48% |
| Profit Margin | n/a |
| EBITDA Margin | -278.95% |
| EBIT Margin | -280.59% |
| FCF Margin | n/a |
Dividends & Yields
LON:0H8T does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.73% |
| Shareholder Yield | -10.73% |
| Earnings Yield | -109.11% |
| FCF Yield | -16.68% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0H8T has an Altman Z-Score of -4.79. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.79 |
| Piotroski F-Score | n/a |